Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.54 |
| ▸ | FEN1 | P39748 | 3/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13038567 | 0.83 | NOS3 (0.46) | METFEN1ALOX5APNOS3NOS1 | |
| SCHEMBL28510567 | 0.82 | MET (0.62) | METFEN1ALOX5APNOS3NOS1 | |
| SCHEMBL29631575 | 0.82 | MET (0.55) | METFEN1ALOX5APNOS3NOS1 | |
| SCHEMBL1136810 | 0.82 | MET (0.55) | METFEN1ALOX5APNOS3NOS1 | |
| Hydrochloric Acid SCHEMBL1137241 | 0.81 | MET (0.54) | METFEN1ALOX5APNOS3NOS1 | |
| SCHEMBL12499981 | 0.80 | NOS3 (0.49) | METFEN1ALOX5APNOS3NOS1 | |
| SCHEMBL13038563 | 0.79 | MET (0.49) | METFEN1ALOX5APMAPK14BRAF | |
| SCHEMBL30844467 | 0.77 | HSPB1 (0.53) | METFEN1ALOX5AP | |
| SCHEMBL197935 | 0.77 | HSPB1 (0.53) | METFEN1ALOX5AP | |
| SCHEMBL13639098 | 0.76 | NOS3 (0.47) | METFEN1ALOX5APNOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288538-B2 | Pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7855290-B2 | N-[4-({2-[({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; hepatocyte growth factor receptor (HGFR) inhibitors; antitumor, -carcinogenic, -metastasis agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20100075944-A1 | NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) | MATSUSHIMA TOMOHIRO | 2010-03-25 | — | — | US | disclosed |
| US-7531532-B2 | Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | MET 545/4885FEN1 2244/4885ALOX5AP 2993/4885 |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | HGF, HGFAC, MET | MET 3/4885FEN1 612/4885ALOX5AP 1496/4885 |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | HGF, MET, FLT4 | MET 2/4885FEN1 2951/4885ALOX5AP 4842/4885 |
| US-20100075944-A1 | NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) | HGF, MET, HDGF | MET 2/4885FEN1 3058/4885ALOX5AP 4813/4885 |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | MET 3/4885FEN1 527/4885ALOX5AP 1155/4885 |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885FEN1 612/4885ALOX5AP 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.